Shares of Emcure Pharmaceuticals fell about 2% in early Mumbai trading on 4 July after a large block deal in which roughly 45.51 lakh shares—equivalent to 2.4% of the company’s equity—changed hands at ₹1,262 apiece, valuing the transaction at roughly ₹574 crore. People familiar with the matter said Bain Capital-backed BC Investments IV was the seller, trimming its stake through the off-market trade. The floor price for the sale was set at ₹1,279.80 a share, indicating a modest discount to the previous close. Kotak Securities handled the transaction. The divestment comes after a year of volatile trading for Emcure, whose stock is down about 13% in 2025 but still trades roughly 27% above its July 2024 listing price. Promoters hold about 78% of the company, while public shareholders own around 16%. For the quarter ended March, the Pune-based drugmaker reported a 64% year-on-year jump in net profit to about ₹189 crore on revenue of ₹2,116 crore, buoyed by double-digit growth in both domestic women’s health and international businesses.